I don't think institutions are quite ready until the FDA requirements are clearer, which is a pity. Also there isn't much of a free float so they would be concerned they couldn't get many without paying a premium. That's the downside of a tight register and of introducing Keysight as a sole investor in the last capital raise rather than going through brokers/local institutions. They (institutions/brokers) didn't get a look in, so they might put the company on ice.
That leaves retail and I don;t know if brokers are writing research on the company. If anyone has seen any, it would be good to know.
Ann: First Responder Device Unveiled, page-27
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.87 |
Change
-0.015(0.80%) |
Mkt cap ! $159.4M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.87 | $19.43K | 10.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 855 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 2941 | 1 |
View Market Depth
| Last trade - 15.38pm 06/11/2024 (20 minute delay) ? |
| EMV (ASX) Chart |